Connor, Clark & Lunn Investment Management Ltd. Monte Rosa Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Nov 13, 2023	BUY	$4.78 - $7.22 $10,501 - $15,862	2,197 Added 17.64%	14,655 $70,000
Q2 2023 Aug 10, 2023	BUY	$4.53 - $8.4 $56,434 - $104,647	12,458 New	12,458 $85,000

Others Institutions Holding GLUE

# of Institutions

Shares Held

43.9M

Call Options Held

141K

Put Options Held

31.2K

Nea Management Company, LLC Timonium, MD

7.69M
Shares

$70.1 Million
3.11% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.6M
Shares

$60.1 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

5.79M
Shares

$52.7 Million
0.46% of portfolio
Baker Bros. Advisors LP New York, NY

4.92M
Shares

$44.8 Million
0.28% of portfolio
Suvretta Capital Management, LLC New York, NY

2.66M
Shares

$24.2 Million
0.55% of portfolio

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $426M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account